Cargando…
Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis (RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms (SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in pharmacokinetics of ABA....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233911/ https://www.ncbi.nlm.nih.gov/pubmed/34207385 http://dx.doi.org/10.3390/jpm11060573 |
_version_ | 1783713960253456384 |
---|---|
author | Márquez Pete, Noelia Maldonado Montoro, María del Mar Pérez Ramírez, Cristina Martínez Martínez, Fernando Martínez de la Plata, Juan Enrique Daddaoua, Abdelali Jiménez Morales, Alberto |
author_facet | Márquez Pete, Noelia Maldonado Montoro, María del Mar Pérez Ramírez, Cristina Martínez Martínez, Fernando Martínez de la Plata, Juan Enrique Daddaoua, Abdelali Jiménez Morales, Alberto |
author_sort | Márquez Pete, Noelia |
collection | PubMed |
description | Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis (RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms (SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in pharmacokinetics of ABA. An observational cohort study was conducted in 120 RA Caucasian patients treated with ABA for 6 and 12 months. Patients with the FCGR2A rs1801274-AA genotype (FCGR2A-p.131His) showed a better EULAR response (OR = 2.43; 95% CI = 1.01–5.92) at 12 months and low disease activity (LDA) at 6 months (OR = 3.16; 95% CI = 1.19–8.66) and 12 months (OR = 6.62; 95% CI = 1.25–46.89) of treatment with ABA. A tendency was observed towards an association between the FCGR3A rs396991-A allele (FCGR3A-p.158Phe) and better therapeutic response to ABA after 12 months of treatment (p = 0.078). Moreover, we found a significant association between the low-affinity FCGR2A/FCGR3A haplotypes variable and LDA after 12 months of ABA treatment (OR = 1.59; 95% CI = 1.01–2.58). The clinical variables associated with better response to ABA were lower age at starting ABA (OR = 1.06; 95% CI = 1.02–1.11) and greater duration of ABA treatment (OR = 1.02; 95% CI = 1.01–1.04), lower duration of previous biological therapies (OR = 0.99; 95% CI = 0.98–0.99), non-administration of concomitant disease-modifying antirheumatic drugs (DMARDs) (OR = 24.53; 95% CI = 3.46–523.80), non-use of concomitant glucocorticoids (OR = 0.12; 95% CI = 0.02–0.47), monotherapy (OR = 19.22; 95% CI = 2.05–343.00), lower initial patient’s visual analogue scale (PVAS) value (OR = 0.95; 95% CI = 0.92–0.97), and lower baseline ESR (OR = 0.92; 95% CI = 0.87–0.97). This study showed that high-affinity FCGR2A-p.131His variant, low-affinity FCGR3A-p.158Phe variant, and combined use of FCGR2A/FCGR3A genetic variations could affect ABA effectiveness. Further studies will be required to confirm these results. |
format | Online Article Text |
id | pubmed-8233911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82339112021-06-27 Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis Márquez Pete, Noelia Maldonado Montoro, María del Mar Pérez Ramírez, Cristina Martínez Martínez, Fernando Martínez de la Plata, Juan Enrique Daddaoua, Abdelali Jiménez Morales, Alberto J Pers Med Article Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis (RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms (SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in pharmacokinetics of ABA. An observational cohort study was conducted in 120 RA Caucasian patients treated with ABA for 6 and 12 months. Patients with the FCGR2A rs1801274-AA genotype (FCGR2A-p.131His) showed a better EULAR response (OR = 2.43; 95% CI = 1.01–5.92) at 12 months and low disease activity (LDA) at 6 months (OR = 3.16; 95% CI = 1.19–8.66) and 12 months (OR = 6.62; 95% CI = 1.25–46.89) of treatment with ABA. A tendency was observed towards an association between the FCGR3A rs396991-A allele (FCGR3A-p.158Phe) and better therapeutic response to ABA after 12 months of treatment (p = 0.078). Moreover, we found a significant association between the low-affinity FCGR2A/FCGR3A haplotypes variable and LDA after 12 months of ABA treatment (OR = 1.59; 95% CI = 1.01–2.58). The clinical variables associated with better response to ABA were lower age at starting ABA (OR = 1.06; 95% CI = 1.02–1.11) and greater duration of ABA treatment (OR = 1.02; 95% CI = 1.01–1.04), lower duration of previous biological therapies (OR = 0.99; 95% CI = 0.98–0.99), non-administration of concomitant disease-modifying antirheumatic drugs (DMARDs) (OR = 24.53; 95% CI = 3.46–523.80), non-use of concomitant glucocorticoids (OR = 0.12; 95% CI = 0.02–0.47), monotherapy (OR = 19.22; 95% CI = 2.05–343.00), lower initial patient’s visual analogue scale (PVAS) value (OR = 0.95; 95% CI = 0.92–0.97), and lower baseline ESR (OR = 0.92; 95% CI = 0.87–0.97). This study showed that high-affinity FCGR2A-p.131His variant, low-affinity FCGR3A-p.158Phe variant, and combined use of FCGR2A/FCGR3A genetic variations could affect ABA effectiveness. Further studies will be required to confirm these results. MDPI 2021-06-18 /pmc/articles/PMC8233911/ /pubmed/34207385 http://dx.doi.org/10.3390/jpm11060573 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Márquez Pete, Noelia Maldonado Montoro, María del Mar Pérez Ramírez, Cristina Martínez Martínez, Fernando Martínez de la Plata, Juan Enrique Daddaoua, Abdelali Jiménez Morales, Alberto Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis |
title | Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis |
title_full | Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis |
title_fullStr | Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis |
title_full_unstemmed | Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis |
title_short | Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis |
title_sort | influence of the fcgr2a rs1801274 and fcgr3a rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233911/ https://www.ncbi.nlm.nih.gov/pubmed/34207385 http://dx.doi.org/10.3390/jpm11060573 |
work_keys_str_mv | AT marquezpetenoelia influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis AT maldonadomontoromariadelmar influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis AT perezramirezcristina influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis AT martinezmartinezfernando influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis AT martinezdelaplatajuanenrique influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis AT daddaouaabdelali influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis AT jimenezmoralesalberto influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis |